10x Genomics, Inc. (TXG) Stock Price & Analysis

10x Genomics, Inc. (TXG) is trading at USD 82.62, down 1.20% today, as of October 29, 2026 at 16:05 UTC (US market open; quotes may be delayed), according to Nexqual market data.

TXG last closed at USD 83.62; today's session has ranged USD 80.08–84.4 on volume of 756,923 shares. Market capitalization is $10.76B, with a 52-week range of USD 12.34–102.81 (NMS). Source: Nexqual, retrieved October 29, 2026 at 16:06 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TXG.md

Key facts (TXG)

• Last four reported quarters (through Jun 30, 2026): revenue $617M, net income -$75.1M (-12.2% margin), free cash flow $121M (SEC filings).
• Insider open-market sales, last ~7 months: 17 Form 4 filings, $14.9M; 7 not under a Rule 10b5-1 plan ($6.2M); 0 by opportunistic insiders, 8 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.61 on a 1–5 scale) (18 analysts), mean target USD 77.5 (range 50–110).
• Total return with dividends: 1Y +540.4% vs S&P 500 +13.2%; 5Y -48.8% vs S&P 500 +79.2%.
• Next earnings: 2026-11-05, EPS estimate USD -0.02, revenue estimate $148M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TXG)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TXG)

P/S 17.4x · P/FCF 88.6x · P/B 13.0x · FCF yield 1.13% · Earnings yield -0.70%

Insider sales (SEC Form 4, open-market, last ~7 months) (TXG)

10 of 17 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (TXG)

Consensus Hold (mean 2.61 on a 1–5 scale), 18 analysts; mean target USD 77.5 (low 50, high 110).

Rating changes, last 120 days:

Total return (dividends reinvested) (TXG)

TXG earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

TXG recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

TXG revenue by product line (quarter ended Jun 30, 2026)

TXG revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

TXG company outlook (results filed Aug 6, 2026)

• “Financial Guidance 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million.”
• “Webcast and Conference Call Information 10x Genomics will host a conference call to discuss the second quarter 2026 financial results, business developments and outlook after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time.”

Quoted word-for-word from the SEC 8-K results press release.

TXG analyst estimates and revisions

TXG options: expected move

Options price a move of about ±20.7% (±$17.25) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5.3% on average.

30-day implied volatility 98.4% vs 91% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 16:06 UTC)

Technical Analysis (TXG)

Nexqual's technical model rates TXG "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of October 29, 2026 at 16:06 UTC.

Analyst Ratings (TXG)

Wall Street analysts rate TXG "Hold" based on 18 analysts, with a mean price target of USD 77.5 (range USD 50–110), per Nexqual as of October 29, 2026 at 16:06 UTC.

Earnings (TXG)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Financials & Fundamentals (TXG)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Financial Health Score (TXG)

Nexqual rates 10x Genomics, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 16:06 UTC.

Ownership (TXG)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

Leadership (TXG)

10x Genomics, Inc. is led by Serge Saxonov, Co-Founder, CEO & Director, per Nexqual as of October 29, 2026 at 16:06 UTC.

Major Backers & Investors (TXG)

Notable institutional backers of 10x Genomics, Inc. include FMR, LLC, ARK Invest, Quantinno Capital Management, LP, according to Nexqual as of October 29, 2026 at 16:06 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 16:06 UTC.

From 10x Genomics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)

Key Strengths & Strategy (as disclosed to the SEC)

• We estimate a total addressable market of more than $21 billion annually, assuming every lab or company in the global life sciences research tools market were to adopt our solutions at spend levels comparable to our existing users.
• We estimate a serviceable addressable market of more than $13 billion annually, assuming every lab or company in the global life sciences research tools market that is currently using single cell, spatial or adjacent research techniques were to adopt our solutions at spend levels comparable to our existing users.
• Not for use in diagnostic procedures." Products that are intended for RUO and are properly labeled as RUO are exempt from compliance with the FDA's requirements applicable to medical devices more generally, including the requirements for clearance or approval and compliance with manufacturing requirements known as the Quality System Regulation.
• Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.

Partnerships

• In September 2013, we entered into an exclusive license agreement with the President and Fellows of Harvard University ("Harvard"), pursuant to which we in-license exclusive, worldwide rights under certain of Harvard's patents and patents applications in the field of sequencing sample preparation and single cell analysis ("Harvard Agreement").
• In September 2020, we entered into an exclusive license agreement with The Board of Trustees of the Leland Stanford Junior University ("Stanford"), pursuant to which we in-license exclusive, worldwide rights under certain of Stanford's patents and patents applications directed to ATAC-seq technology in all field of use ("Stanford Agreement").

Legal & Regulatory Risks (Item 1A, quoted)

• Our products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay or prevent commercialization of our products, thereby materially and adversely affecting our business, financial condition, results of operations and prospects.
• Our products, if used for the diagnosis of disease or in other clinical settings, would likely be subject to government regulation, and the regulatory approval and maintenance process for such products may be expensive, time-consuming and uncertain both in timing and in outcome. Since our strategy includes our potential participation in clinical markets, we will be increasingly exposed to these risks.
• We anticipate that certain of our products could in the future be available through laboratories that are certified under the CLIA.
• We are subject to risks related to taxation in multiple jurisdictions and changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 16:06 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt